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InhibitionIn this work four cationic additives were used to improve the surface activity of lung surfactants, particularly
in the presence of bovine serum that was used as a model surfactant inhibitor. Two of those additives were
chitosan in its soluble hydrochloride form with average molecular weights of 113kDa and 213kDa. The other
two additives were cationic peptides, polylysine 50kDa and polymyxin B. These additives were added to
bovine lipid extract surfactant (BLES) and the optimal additive–surfactant ratio was determined based on the
minimum surface tension upon dynamic compression, carried out in a constrained sessile drop (CSD) device
in the presence of 50 μl/ml serum. At the optimal ratio all the BLES-additive mixtures were able to achieve
desirable minimum surface tensions. The optimal additive–surfactant ratios for the chitosan chlorides are
consistent with a previously proposed patch model for the binding of the anionic lipids in BLES to the
positive charges in chitosan. For the peptides, the optimal binding ratios were consistent with ratios
established previously for the binding of these peptides to monolayers of anionic lipids. The optimal
formulation containing these peptides were able to reach low minimum surface tension in systems
containing 500 μl/ml of serum, matching the effectiveness of a lung surfactant extract that had not
undergone post-separation processes and therefore contained all its proteins and lipids (complete lung
surfactant).eering and Applied Chemistry,
adaM5S 3E5. Tel.: +1 416 946
a).
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
There are several conditions that may lead to poor blood
oxygenation associated with respiratory distress syndrome (RDS),
however the lack or malfunction of lung surfactants is one of the most
common conditions linked to this syndrome [1,2]. In pre-term
neonatal patients diagnosed with RDS (neonatal RDS or nRDS) the
syndrome is often associated with the lack of surfactants in the
alveolar ﬂuid. In patients diagnosed with Acute RDS (ARDS) the lungs
may collapse due to surfactant malfunction caused by various
surfactant inhibitors [1,3]. Surfactant therapy (instillation of surfac-
tant extracts from animals) has reduced the mortality of nRDS
patients from nearly 70% to less than 20%, but it has been ineffective in
the treatment of ARDS [3–6].
Various inhibitors are associated with surfactant malfunction,
including proteins like albumin and ﬁbrinogen, and lipids like
cholesterol, lysolecithins and unsaturated fatty acids. Bovine and
human serum has been used as a broad spectrum surrogate to
simulate surfactant inhibition [1,3]. Various formulations can over-come the action of low serum content (<30 μl/ml), but cannot handle
higher serum content [7–9]. To assess the appropriate serum content
to evaluate surfactant inhibition one should consider that bronch-
oalveolar lavages of ARDS patients contain up to 25 mg/ml of albumin
[10]. Since bovine serum contains approximately 40 mg/ml of
albumin suggests that approximately 600 μl/ml of serum is needed
to evaluate surfactant inhibition.
Onemethod used to evaluate surfactant inhibition in vitro involves
measuring the surface tension of exogenous surfactants compressed
and expanded under physiologically relevant conditions. In this work
a constrained sessile droplet device (CSD) is used to measure the
dynamic surface tension using the Axisymmetric Drop Shape Analysis
(ADSA) [2,11–13]. Surfactant inhibition is typically characterized by
either high minimum surfactant tension (γmin>5 mJ/m2) and/or
catastrophic ﬁlm collapse (ﬁlm collapse at high surface tensions) [1].
A typical surface tension–area–volume ADSA-CSD output for these
studies is presented in Fig. 1 for a 2 mg/ml bovine lung extract
surfactant (BLES) with 10 μl/ml of bovine serum, and a complete
bovine lung surfactant with 750 μl/ml serum. This complete surfac-
tant of Fig. 1 was obtained by saline lavage from calf lungs and simply
lyophilized without further solvent separation steps (used to produce
BLES) that remove surfactant proteins SP-A and SP-D and part of the
proteins SP-B and SP-C. As indicated by Fig. 1, a common exogenous
surfactant (BLES) cannot reach low surface tensions (γmin~20 mJ/m2)
Fig. 1. Dynamic surface tension, area and volume output from ADSA for (a) 2 mg/ml BLES in the presence of 10 µl/ml serum, and (b) complete lung surfactant (~2 mg/ml) in the
presence of 750 µl/ml serum. Dynamic cycling conditions: 20% compression (reduction in area), 3 s/cycle, 100% R.H., 37 °C.
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complete lung surfactant can produce minimum surface tensions of
5 mJ/m2 or less even in the presence of 750 μl/ml of serum.
The difference between BLES and the complete lung surfactant
used in Fig. 1 is that in order to produce BLES the surfactant lavage has
undergone further puriﬁcation with organic solvents that remove the
hydrophilic surfactant proteins SP-A and SP-D, part of the cholesterol,
and part of the surfactant proteins SP-B and SP-C [2,6]. Furthermore,
the process of solvent extraction may also disrupt the original
structure of lipid–protein complexes. Several additives have been
proposed in order to make up for these changes in surfactant
compositions. For example, neutral and hydrophilic polymers like
dextran and polyethylene glycol have been used as surfactant
additives [2,7,14–18]. Promising results have been observed in vitro
with these additives, in particular against albumin-induced inhibition,
but there are conﬂicting results in vivo [19]. Furthermore, mixtures of
BLES and polyethylene glycol evaluated with ADSA-CSD were
effective against 2.5 mg/ml albumin, but ineffective against 10 μl/mlof serum [20]. Anionic polymers such as hyaluronan and mucins have
been found effective at reversing serum inhibition [20–22]. Nonionic
and anionic polymers are said to simulate the role of SP-A in the
preparations [2,7,18]. On the other hand, a cationic polysaccharide,
chitosan, has been found to be more effective than nonionic and
anionic polymers, and produce formulations that are consistently
active regardless of the batch to batch variability of the extract [23,24].
A recent study has shown that chitosan chloride is effective at
resisting the action of various inhibitors including albumin, ﬁbrino-
gen, serum (50 μl/ml), and cholesterol [25]. Other cationic additives
like polylysine, recombinant surfactant protein-C, synthetic peptide
KL4 and the biosurfactant polymyxin B have been proposed as
additives that simulate the role of proteins SP-B and SP-C, which are
essential for lung surfactant activity [26–30]. However, their effec-
tiveness against high serum content has not been evaluated. These
ﬁndings led to the hypothesis that using the proper concentration of
cationic additives in BLES it is possible to overcome serum levels that
simulate the inhibitory conditions of ARDS patients. In this work, four
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113 kDa and 213 kDa; polylysine (50 kDa); and polymyxin B—were
evaluated as additives in BLES preparations containing various levels
of bovine serum. The molecular structure of these cationic additives
is illustrated in Fig. 2. Dynamic surface tensions obtained using
ADSA-CSD were used to assess the activity of these formulations. Zeta
potential measurements were used to assess the binding of these
cationic additives to the anionic lipids in the surfactant aggregates.
2. Materials and methods
2.1. Materials
BLES (bovine lipid extract surfactant) was provided by BLES
Biochemicals Inc., London, Ontario, Canada. BLES is an organic solvent
extract from a bovine source, and contains mainly phospholipids and
two surfactant-associated proteins, SP-B and SP-C. Concentrated
(27 mg/ml) BLES samples were stored in glass vials under N2
atmosphere at−20°C until the day of the experiment. The suspension
of the complete lung surfactant was also provided by BLES
Biochemicals.Fig. 2.Molecular structures of (a) chitosan chlorides (protasans), (b) polylysine, and (c)
polymyxin B.Chitosan hydrochloride (Protasan Cl) 113 kDa and 213 kDa were
purchased from Novamatrix, FMC BioPolymer AS, Drammen (Nor-
way) (Protasan UP Test Kit, #4219001). These water-soluble
chitosans have a degree of deacetylation of 75–90%. Protasan 113
contains a distribution of molecules with molecular weights ranging
from 50,000 to150,000 g/mol and protasan 213 contains molecules
ranging from 150,00 to 400,000 g/mol. Poly-D-lysine hydrobromide
was purchased from Sigma-Aldrich and contain molecules ranging
from 30,000 to 70,000 g/mol (product code P-2636). Polymyxin B
(molecular weight 1301 g/mol) was purchased from Sigma-Aldrich
(product code P1004). Bovine serum was also purchased from Sigma-
Aldrich (product code B8655) (Lot No. 127H9001, protein content:
60 mg/ml determined by the Biuret method).
2.2. Methods
2.2.1. Sample preparation
Frozen BLES (27 mg lipids/ml as received) samples were thawed
in a 37.5 °C water bath for 1h, before being diluted in a salt solution
containing 0.6% NaCl and 1.5 mM CaCl2 [41,42]. The concentration of
BLES was 2 mg/ml in all preparations. The prescribed amount of a
stock solution of the cationic additive (chitosan chloride 2 mg/ml,
polylysine 1.0 mg/ml, and polymyxin B 1.0 mg/ml) was added to the
NaCl/CaCl2 salt solution. Various concentrations of each cationic
additive were also evaluated, ranging from 0 to 0.3 mg/ml. The pH of
these BLES–cationic additive preparations ranged from 5.3 to 5.7.
Bovine serum (stored in aliquots at −20 °C) was added to the
surfactant mixture. The ﬁnal pH of these BLES–cationic additive–
serum mixtures ranged from 6.5 to 7.0.
2.2.2. Surface tension measurements
The BLES–cationic additive–serum preparations were gently
mixed using a Vortex-Genie, Model K-550-G mixer, and their surface
activities were examined using a Constrained Sessile Drop (CSD)
conﬁguration in conjunction with Axisymmetric Drop Shape Analysis
(ADSA). The design and operation of the CSD conﬁguration has been
described in detail elsewhere [13,23,24]. Brieﬂy, to start any CSD
operation, a sessile drop of the test liquid is formed on a circular
horizontal surface of a stainless steel pedestal (3 mm diameter). The
pedestal has a sharp-knife edge (60° angle of approach) to prevent the
spread of the test liquid when the surface tension reaches a near zero
value at the end of the compression stage. During the experiments the
droplet and the pedestal are enclosed in a chamber that allows control
of humidity and temperature of the air in the chamber to 100%
relative humidity at 37 °C. The liquid drop was ﬁrst left undisturbed
for 3min or until the equilibrium surface tension of ~25 mJ/m2 was
reached. Dynamic expansion and compression cycles of the test
droplet were carried out at a periodicity of 3s/cycle. The ratio
between the interfacial area reached at the end of compression to the
initial area was adjusted to approximately 20%, in order to mimic
normal breathing in adults [1,13,31]. Sequential images (20 images/s)
of the drop during dynamic cycling were collected by a CCD camera
(Model 4815-5000, Cohu Corp., Poway, CA), and later analyzed by
ADSA to get a typical output including surface tension, surface area
and volume of the test drop [12,13,24].
For each of the formulations presented in this paper, four or more
droplets were tested and the results are expressed as the mean±95%
conﬁdence interval (n ≥4 unless otherwise indicated). Typical surface
tension–volume–area outputs of ADSA for BLES–serum and for
complete lung surfactant–serum during dynamic cycling are pre-
sented in Fig. 1. Using these data, dynamic cycling isotherms can be
obtained by plotting the surface tension versus the relative area of the
droplet (area at any time divided by themaximum surface area during
the cycle). The dynamic cycling isotherms for the systems of Fig. 1 are
presented in Fig. 3.
Fig. 3. Cycling isotherms (dynamic surface tension versus relative surface area)
(a) 2 mg/ml BLES in the presence of 10 µl/ml serum, and (b) complete lung surfactant
(~2 mg/ml) in the presence of 750µl/ml serum. Dynamic cycling conditions: 20%
compression (reduction in area), 3 s/cycle, 100% R.H., 37 °C.
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The zeta potential of the surfactant aggregates was determined
using a Delsa 440SX Zeta Potential Analyzer (Coulter-Beckman,
Miami, FL). To prevent the saturation of the light scattering detectors,
each sample was diluted by a factor of 10 in a 0.9% NaCl solution.
Additional information on this method is available elsewhere [24].
3. Results
3.1. Surface activity of BLES and complete lung surfactant
Fig. 1 shows that the minimum surface tension of BLES+10 μl/ml
of serum is close to 22 mJ/m2, and for complete lung surfactant+
750 μl/ml serum it is close to 5 mJ/m2. This indicates that this BLES
preparation is inactivated by 10 μl/ml serum since it cannot achieve
low minimum surface tensions (~5 mJ/m2 or less) when compressed
at 20% compression (fractional reduction in surface area) with a
3second/cycle periodicity, in 100% R.H. air at 37 °C (physiological
conditions). It is important to note that the surface activity of
surfactants in 100% R.H. air is markedly less than in dryer air at R.H.
<100% R.H [13,32,33].
The data in Fig. 1 can also be used to produce a cycling isotherm by
plotting the surface tension versus the relative area during cycling.
Fig. 3 presents the cycling isotherms for the BLES–serum and
complete lung surfactant–serum systems. The solid symbols in Fig. 3
represent the data obtained during the compression stage, and the
open symbols the data obtained during the expansion stage. In Fig. 3a(BLES–serum) one observes that by reducing the area by more than
10% of its maximum value there is no further reduction in surface
tension (i.e. ﬁlm collapse). In Fig. 3b (complete lung surfactant–
serum) there is also ﬁlm collapse but in this case it takes place at low
surface tensions (~3 mJ/m2), and therefore is not a cause for concern.
The reduction in surface tension with reduction in relative area (slope
in Fig. 3b) is steep, corresponding to a high ﬁlm elasticity (ε=[A/Ao]
dγ/d[A/Ao]) [13]. Finally, Fig. 3b also illustrates the relaxation of the
surfactant ﬁlm, characterized by an increase in the surface tension
after the compression of the ﬁlm has ended and before the expansion
commenced. Although this feature of the compression cycle of ADSA-
CSD might not be physiologically correct in all cases, it gives the
opportunity to study the stability of the ﬁlm. Film relaxation is
generally undesirable as it reﬂects instability of the ﬁlm. Furthermore
it is important to clarify that ﬁlm relaxation is typically observed in
systems exposed to 100% R.H. at 37 °C [13].3.2. Surface activity of BLES+cationic additives
In order to evaluate the surface activity of BLES with cationic
additives in the presence of 50 μl/ml serum, their minimum surface
tension during dynamic cycling was obtained, as a function of the
concentration of the cationic additive. Fig. 4 presents the minimum
surface (γmin) tensions obtained with mixtures of BLES and chitosan
chlorides (protasans), polylysine, and polymyxin B. For the case of
protasans (Fig. 4a), between 0.15 and 0.2 mg/ml of the polymer the
minimum surface tension is below 5 mJ/m2. This range of concentra-
tion is consistent with that obtained by Saad et al. in the absence of
inhibitors, and is slightly higher than the one reported by Kang et al.
for chitosan (not chitosan hydrochloride) mixed with 2 mg/ml of
BLES [24,25]. The data in Fig. 4a also suggest that optimal formulations
(lower γmin) with 2.0 mg/ml BLES require less protasan 113 kDa
(~0.15 mg/ml) than protasan 213 kDa (~0.2 mg/ml). Furthermore,
the “V” shape of the minimum surface tension curves in Fig. 4 has
been observed before in the case of chitosan–BLES mixtures. In those
cases, it has been proposed that an overdose of chitosan leads to a
hydration and ﬂuidization of the ﬁlm, and ﬁlm collapse [24].
For the case of peptides, polylysine and polymyxin B an optimal
additive concentration was also found in each case. For polymyxin B
this occurs at a relatively low concentration (near 0.1 mg/ml, or 5% on
a weight basis) but for polylysine this occurs at the relatively high
concentration of 0.2 to 0.25 mg/ml of the peptide (~10% w/w). These
ﬁndings are consistent with those of Calkovska et al. who found that
curosurf (a porcine-extracted surfactant) with 2% of polymyxin B
outperformed curosurf alone when challenged with albumin as
inhibitor, reducing the frequency of lung collapse in rabbits [29]. A
previous experience with polylysine as surfactant additive was not
successful [27]. As will be discussed later, recent studies suggest that
the problem with those earlier studies is that the molecular weight of
polylysine (14 kDa) was too low to produce any signiﬁcant binding
with the anionic lipids. One interesting observation with regards to
peptides is that their overdose effect is not as pronounced as that
experienced by the polysaccharides. This is a desirable feature for
cationic peptide formulations, as it suggests that these formulations
are more robust than the ones based on cationic polysaccharides.
Fig. 5 presents the dynamic cycling isotherms for these prepara-
tions. In the case of the low molecular weight protasan (113 kDa),
there is no ﬁlm collapse observed, and no relaxation, leading to
systems with minimal hysteresis. For the case of the higher molecular
weight protasan (213 kDa) no ﬁlm collapse was observed, but
substantial relaxation was noticeable at the end of the compression
step, suggesting that protasan 213 kDa formulations are less stable.
The preparations containing polylysine and polymyxin experienced
some ﬁlm collapse at surface tensions near 3 mJ/m2 and no signiﬁcant
relaxation.
Fig. 4. Minimum surface tension of mixtures of 2 mg/ml BLES in the presence of 50µl/ml serum as a function of cationic polymer concentration. Dynamic cycling conditions: 20%
compression (reduction in area), 3 s/cycle, 100% R.H., 37 °C.
Fig. 5. Cycling isotherms for the optimal formulations of Fig. 4. All formulations contain 2 mg/ml BLES and 50µl/ml bovine serum. The concentration of the optimal cationic additive
is (a) 0.15 mg/ml protasan 113 kDa, (b) 0.20 mg/ml protasan 213 kDa, (c) 0.1 mg/ml polymyxin B, and (d) 0.2 mg/ml polylysine 50 kDa. Dynamic cycling conditions: 20%
compression (reduction in area), 3 s/cycle, 100% R.H., 37 °C.
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Previous work has shown that the zeta potential of the surfactant
aggregates reﬂects the binding of chitosan to BLES [24]. In that case,
the binding of this cationic polymer to the negatively chargedsurfactant aggregates reverses the charge of these aggregates with
increasing chitosan concentration. The same transition is observed for
BLES–protasanmixtures in Fig. 6a. For these polysaccharides there is a
substantial increase in the charge of the aggregates within the range
of 0 to 0.1 mg/ml for protasan 113 kDa and from 0 to 0.15 mg/ml for
Fig. 6. Zeta potential of the aggregates of mixtures of 2 mg/ml BLES in mixture with (a) cationic polysaccharides (protasan 113 kDa and 213 kDa), and (b) cationic peptides
(polymyxin and polylysine); as a function of the concentration of the cationic additive. pH=5.5, electrolyte solutions containing 0.9% NaCl.
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produces a marginal increase in the charge of the aggregates. The
transition into this region of marginal zeta potential increase has been
associatedwith the optimal formulation in the case of BLES+chitosan
preparations [24]. In this case, the transition points observed for
BLES+protasan are also consistent with the optimal formulations
reported in Fig. 4. Furthermore, the fact that the transition into the
marginal region takes place at a lower protasan 113 kDa concentra-
tion than that of protasan 213 kDa suggests that protasan 113 kDa
binds more strongly to the anionic lipids in BLES.
For the cationic peptides polylysine and polymyxin (Fig. 6b), the
zeta potential does not turn positive, but it does shift towards higher
zeta potential values. For the case of polymyxin there is a clear plateau
region after 0.05 mg/ml of polymyxin (2.5% mass basis), which is
consistent with the data in Fig. 4b that shows that desirable minimum
surface tensions are obtained using 0.05 mg/ml to 0.1 mg/ml of
polymyxin. For polylysine, the change in zeta potential is more
gradual and it only appears to approach a plateau value at
concentrations close to 0.20 to 0.25 mg/ml of the peptide. The fact
that the cationic peptides do not produce the highly positively
charged aggregates obtained with cationic polysaccharides suggests
that the binding between these types of additives and BLES is different
from that of chitosans and BLES.
To illustrate the effect of cationic additive binding on surfactant
aggregation, Fig. 7 presents micrographs of BLES–cationic additive
preparations formulated at the optimal conditions identiﬁed in Fig. 4.
To interpret these results it is important to keep in mind that BLES
without additives produces a suspension of 10–20 μmvesicles, as seen
in BLES-only micrographs presented in previous articles [23,24]. The
images in Fig. 7 show that using all these cationic additives at optimal
formulation conditions induces the formation of larger surfactant
aggregates. The same observation has been made previously when
using chitosan as cationic additive [23,24].
3.4. Resistance of cationic additives–BLES against serum inhibition
Themaximumserumcontent that canbehandledbyBLES+cationic
additiveswasevaluatedbydetermining theminimumsurface tensionof
these optimal formulations (from Fig. 4) as a function of serum content.
These minimum tensions are presented in Fig. 8.
For BLES alone, even as little as 10 μl/ml of serum is enough to
inhibit this surfactant preparation. With protasans, the formulation
retains its surface activity in the presence of 50 μl/ml of serum, but
they become inactive when the serum content increases to 100 μl/ml.On the other hand, the polylysine formulation retains its surface
activity in the presence of 500 μl/ml of serum, but they are inactive in
750 μl/ml of serum. Finally, polymyxin B produces a similar minimum
surface tension to that of complete lung surfactant throughout the
range of serum content of 0 to 750 μl/ml. Thus, by combining 2 mg/ml
BLES with 0.1 mg/ml polymyxin B it is possible to simulate the
inhibition resistance of complete lung surfactant.
Fig. 9 presents the dynamic cycling isotherm for 2 mg/ml BLES+
0.1 mg/ml polymyxin B in the presence of 750 μl/ml of serum, and a
superimposed isotherm for the complete lung surfactant (Fig. 3b).
While both formulations can reach low surface tensions, the complete
surfactant can reach this low tensionwith only 10% compression,which
is indicative of the higher elasticity of the surfactant ﬁlm.
4. Discussion
The differences in surface activity of BLES and complete lung
surfactant in the presence of serum, as illustrated by Figs. 1 and 3,
should be seen in light of themethods used to extract lung surfactants
from intact bovine lungs. In the case of the complete lung surfactant, a
saline solution is used to wash the lungs, and is later lyophilized to a
concentrated solution. Thus none of the proteins or lipids of the lung
surfactants is removed. On the other hand, BLES requires two
additional puriﬁcation steps. The ﬁrst step involves an extraction
with chloroform and methanol to recover the lipids and remove the
hydrophilic proteins SP-A and SP-D. The second step involves the
removal of cholesterol and neutral lipids from the surfactant extract
through an “acetone” wash.
The surfactant protein SP-A is the most abundant of the four
surfactant proteins (~7% in the complete surfactant), it has a large
molecular weight (~30 kDa) and it assembles in a tertiary structure of
up to 750kDa. SP-A has been associated with tubular myelin
formation and the spreading of the surfactant ﬁlm at the air/water
interface [34,35]. In the case of cholesterol, its role on lung surfactant
physiology is more controversial since at low concentration (~5% of
total lipids) it improves the mechanical properties of the ﬁlm, but at
high concentrations it ﬂuidizes the surfactant ﬁlm, inhibiting
formulation [36,37].
Besides the loss of SP-A and cholesterol, the solvent extraction
method used in the preparation of BLES and other commercial
surfactant extracts also removes between 50% and 80% of the cationic
and hydrophobic surfactant proteins SP-B and SP-C [2,6]. The
positively charged surfactant protein SP-B (molecular weight
~9 kDa) is an essential protein since its absence from lung surfactants
Fig. 7.Micrographs of optimal formulations of BLES and cationic additives. All formulations contain 2 mg/ml BLES, and: (a) 0.15 mg/ml protasan 113 kDa, (b) 0.20 mg/ml protasan
213 kDa, (c) 0.1 mg/ml polymyxin B, and (d) 0.2 mg/ml polylysine 50 kDa.
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hydrophobic cationic protein SP-C (~4 kDa) is said to be inserted in
the lipid membrane, facilitating the formation of large surfactant
aggregates, tubular myelin formation and ﬁlm spreading [35,40]. The
content of SP-B in complete lung surfactant is typically 1–2% (of the
total lipids), and SP-C is close to 2–3% [2].Fig. 8.Minimum surface tension of optimal formulations of 2 mg/ml BLES and different
cationic cationic additives (formulations of Fig. 5) as a function of bovine serum
content. Dynamic cycling conditions: 20% compression (reduction in area), 3 s/cycle,
100% R.H., 37 °C.Chitosan chlorides and polylysine, similar to SP-B and SP-C, have
positive charges that can bind to anionic lipids, but they do not have
the lipophilic moieties of these proteins. Polymyxin, on the other
hand, has the positive charge characteristic of SP-B and SP-C, and
lipophilic moieties. The lipophilic moieties of polymyxin may explain
the fact that polymyxin outperformed chitosan chlorides and
polylysine in preventing serum inhibition.Fig. 9. Cycling isotherms for 2 mg/ml BLES+0.1 mg/ml polymyxin (circles), and
complete lung surfactant (diamonds) in the presence of 750 μl/ml bovine serum.
Dynamic cycling conditions: 20% compression (reduction in area), 3 s/cycle, 100% R.H.,
37 °C.
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previously discussed for the case of chitosan–BLES preparations [24].
In that work, it was proposed that the cationic groups (−NH3+) of
chitosan bind to patches of anionic lipids (phosphatidylglycerols) in
BLES. That patch hypothesis is consistent with an optimum chitosan
concentration of 0.1–0.15 mg/ml for 2.0 mg/ml of BLES [24], and an
optimal chitosan chloride (protasans) concentration of 0.15–0.2 mg/
ml for 2 mg/ml BLES (Fig. 4a). The hypothesis of patch adsorption is
consistent with thermodynamic models on the adsorption of cationic
proteins on mixed ﬁlms of anionic and neutral lipids [41]. These
patches have been observed in vesicles produced with ﬂuorescence
labeled lipids [42]. Despite the fact that the chitosan chlorides are not
as potent additives to counteract serum inhibition as the cationic
peptides, their possible use in surfactant formulations cannot be
discarded. These polymers displayed excellent properties in resisting
the action of potent inhibitors such as cholesterol and ﬁbrinogen [25].
One interesting property of chitosan is that it can compact molecules
of unsaturated lipids that inhibit surfactant ﬁlms, and thismay explain
their performance as surfactant additives [43]. With regards to safety
issues associated with chitosan chloride in surfactant therapy, it is
noted that micro-particle systems containing protasan 213 kDa are
being used in pulmonary drug delivery [44]. There is also evidence
that chitosan chlorides are compatible with the alveolar epithelial
tissue, and that they do not trigger a cytotoxic response or an increase
in tissue permeability that could lead to lung edema [45].
One of the differences between chitosans and peptides is that
chitosans are rigid molecules that cannot penetrate lipid layers [46],
but peptides are more ﬂexible and could, in principle, inﬁltrate lipid
membranes [47]. It has been proposed that the ability of cationic
proteins SP-B and SP-C to insert themselves in surfactant bilayers is
important in improving the properties of lung surfactants [2,48]. The
lack of membrane insertion ability of chitosans could explain their
inferior performance against serum inhibition. Furthermore, chitosans
are known to adsorb either ﬂat or in loop conformations on surfaces
[49] which suggests that the unbound NH3+ groups of chitosan are
exposed to the aqueous environment, which would explain the highly
positive zeta potential of BLES–chitosan formulations.
The binding between polylysine and anionic lipids has been
explored by various researchers [50–52]. It has been found that
polylysine may adopt alpha-helix, random coils or even beta-sheet
conﬁgurations when bound to anionic or mixed lipid monolayers.
Unfortunately, there is no further conﬁrmation at this time of the
polylysine conﬁguration in BLES–polylysine systems. Thus, further
studies are necessary to investigate the secondary structures of
polylysines bound to lung surfactants and the role of these structures
in improving the properties of lung surfactants. Part of the role of
polylysine in improving surfactant properties may be related to their
ability to dehydrate lipid bilayers [50,52].
With regards to the effect of molecular weight on the binding of
these additives, the data in Figs. 4 and 6 suggest that the lower
molecular weight chitosan chloride has a stronger binding to the
anionic lipids in BLES since it requires less protasan of 113 kDa than
213 kDa to reach the optimal concentration. Considering that their
binding ratio and performance in mixtures with BLES is similar to that
of chitosan 6000 kDa [23,24] one is inclined to conclude that
molecular weight is not a highly signiﬁcant variable in these
formulations. However, that statement should be considered with
some caution as the minimum molecular weight of polymers
evaluated in this study is 50 kDa (i.e. polylysine). It has been found
that polylysine with molecular weights below 15 kDa have a weak
binding or no binding at all to phosphatidylglycerol lipids [50]. This
ﬁnding is consistent with the fact that in a previous study polylysines
with molecular weights of 2.3 to 14 kDa were found to be ineffective
as lung surfactant additives [27].
The use of polylysine in surfactant therapy should be carefully
considered. Polylysine and other cationic proteins have been found totrigger pulmonary edema and to increase the permeability of
epithelial tissue [53,54]. However, in those studies polylysine was
directly administered to the subject, getting polylysine in direct
contact with the epithelial tissue. In the case of polylysine pre-bound
to surfactant lipids it is less likely that polylysine could produce any
signiﬁcant effect on the tissue. However, the safety of polylysine–
surfactant formulations is an issue that should be considered in the
future.
One disadvantage of polylysine compared to SP-B is the lack of
hydrophobic amino acids in its backbone (e.g. proline, isoleucine, and
valine) that are present in the backbone of SP-B. These hydrophobic
amino acids are said to provide surface active properties to SP-B and
further contribute to its insertion into lipid layers [48]. In the case of
SP-C, this peptide has palmitoyl (a C16–16 alkyl carbon fatty acid)
groups connected to an alpha-helix secondary structure rich in valine
[55]. Some of these hydrophobic properties are simulated by
polymyxin B (Fig. 2c). Polymyxin has one hydrophobic group
containing 9 alkyl carbons, and two hydrophobic amino acids: leucine
and phenylalanine. Furthermore, polymyxin B has 5 lysine amino
acids that provide ﬁve cationic binding points with anionic species
like phosphatidylglycerols. Studies on dipalmitoyl phosphatidyl
glycerol (DDPG)–polymyxin B monolayers conﬁrm that this molecule
binds to ﬁve neighboring DPPG molecules, and that at that ratio there
is a shift in the compression isotherm of this mixture, and an increase
in the collapse surface pressure of DPPG [56,57]. Vibrational sum
frequency generation spectroscopy studies suggest that polymyxin B
dehydrates the anionic groups of phosphatidyl glycerol, and that the
lipophilic group of polymyxin B interacts with the lipophilic portion of
the lipid layer [58]. Based on the fact that about 10% of lipids in BLES
are anionic, and using the optimal stoichiometric ratio of 5 anionic
lipids to one polymyxin B, one would predict that the optimal
polymyxin concentration (for 2 mg/ml BLES) is close to 0.07 mg/ml.
This estimated optimal concentration is close to the value of 0.1 mg/
ml polymyxin B obtained from the data of Fig. 4. Based on the data of
Fig. 8, polymyxin B is an excellent additive for BLES, suggesting that all
three properties of this molecule—being cationic, a peptide, and
hydrophobic are relevant to improving the performance of extract
surfactants in the presence of bovine serum.
The use of polymyxin B in surfactant therapy is less of a concern
since this antibiotic has already been used in the treatment of septic
conditions in the lungs [30,58,59]. However, it is important to keep in
mind that polymyxin B is a histamine-releasing agent that may cause
over-responsive (allergic) reactions in some patients [60,61]. These
undesirable responses have been observed when polymyxin is
instilled or inhaled directly into the lungs, but it is expected that
polymyxin pre-bound to lipids would be less active (at histamine
release) than polymyxin alone.
One important point that needs to be addressed is that the optimal
cationic additive/lipid ratio obtained from the data in Fig. 4 cannot be
extrapolated to other surfactant preparations. The lipid composition
in different surfactant extracts can vary, and therefore an optimization
procedure similar to that illustrated in Fig. 4 is necessary in order to
formulate an optimal surfactant preparation. Furthermore, bovine
serum is useful to evaluate the activity of the formulations against
some blood proteins (particularly albumin), but there are other
powerful inhibitors like ﬁbrinogen, cholesterol, and lipases that need
to be considered [62].References
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